Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
This study will treat patients with non-Hodgkin B-cell lymphoma who have relapsed from, refractory or intolerant to prior therapy. This study will help understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer activity as monotherapy.
Non-Hodgkin's B-cell Lymphoma
DRUG: DZD9008
Part A: Incidence of Treatment-Emergent Adverse Events, Incidence of Treatment-Emergent Adverse Events as Assessed by CTCAE v5.0, Through study completion, an average of 1.5 years|Part B: objective response rate (ORR), Through study completion, an average of 1.5 years
Maximum Plasma DZD9008 concentration, up to 16 weeks|Plasma DZD9008 concentration- Area Under the Curve, up to 16 weeks
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Non-Hodgkin B-cell Lymphoma. This study includes dose escalation (Part A) and dose expansion (Part B).